16 August 2022: Original Paper
Evaluation of Deceased Donor Kidney Transplantation in the Eurotransplant Senior Program in Comparison to Standard Allocation
Nelly Delaly Eklou 1BCDE , Bernd M. Jänigen 2E , Przemylsaw Pisarski 2E , Gerd Walz 1E , Johanna Schneider 1ABCDEF*DOI: 10.12659/AOT.936514
Ann Transplant 2022; 27:e936514
Table 1 Baseline characteristics.
| Parameter | ESPn=116 | ETKASn=111 | p-value |
|---|---|---|---|
| Donor age (y) | 69.4±0.3 | 51.7±1.1 | * |
| Recipient age (y) | 69.5±0.4 | 58.1±0.6 | * |
| Sex (male), n (%) | 83 (71.6) | 74 (66.7) | 0.426 |
| Weight (kg) | 74.3±1.1 | 77.5±1.5 | 0.082 |
| Body mass index (kg/m) | 26.2±0.4 | 26.3±0.4 | 0.808 |
| Coexisting disorders | 3.5±0.2 | 2.5±0.1 | * |
| Diabetes, n (%) | 39 (33.9) | 21 (18.9) | * |
| Hypertension, n (%) | 115 (99.1) | 111 (100) | 1.000 |
| Cardiac, n (%) | 91 (78.4) | 46 (41.4) | * |
| Pulmonary, n (%) | 14 (12.1) | 6 (5.4) | 0.101 |
| Hepatic, n (%) | 6 (5.2) | 14 (12.6) | 0.061 |
| Peripheral arterial disease, n (%) | 28 (24.1) | 21 (18.9) | 0.420 |
| Stroke, n (%) | 17 (14.8) | 13 (11.7) | 0.559 |
| Cancer and leukemia, n (%) | 16 (13.8) | 14 (12.6) | 0.846 |
| Others, n (%) | 26 (22.4) | 14 (12.6) | 0.057 |
| Smoking history, n (%) | 28 (24.1) | 25 (22.5) | * |
| Smoking history (pack years) | 19.1±3.3 | 23.0±3.9 | 0.462 |
| Immunosuppressive therapy before transplantation, n (%) | 17 (14.7) | 26 (23.4) | 0.127 |
| Chemotherapy before transplantation, n (%) | 3 (2.6) | 4 (3.6) | 0.717 |
| Cause for ESKD | |||
| Diabetes, n (%) | 17 (14.7) | 10 (9.0) | 0.222 |
| Autoimmune disorders and chronic glomerulonephritis, n (%) | 22 (19.0) | 26 (23.4) | 0.422 |
| Genetic, n (%) | 16 (13.8) | 23 (20.7) | 0.218 |
| Hypertensive, n (%) | 12 (10.3) | 1 (0.9) | * |
| Kidney transplant failure , n (%) | 8 (6.9) | 18 (16.2) | * |
| Others, n (%) | 1 (0.9) | 3 (2.7) | 0.361 |
| Unknown, n (%) | 31 (26.7) | 21 (18.9) | 0.206 |
| Time on dialysis (months) | 66.3±2.7 | 93.2±3.6 | * |
| Time on peritoneal dialysis (months) | 9.4±2.2 | 14.4±3.2 | 0.195 |
| Time on hemodialysis (months) | 57.1±3.5 | 78.0±4.4 | * |
| Kidney transplantations | |||
| 1 transplantation, n (%) | 109 (93.9) | 92 (82.9) | * |
| 2 transplantation, n (%) | 7 (6.0) | 17 (15.3) | * |
| 3 transplantation, n (%) | 0 (0.0) | 2 (1.8) | 0.238 |
| CMV serostatus | |||
| D−/R−, n (%) | 19 (16.7) | 22 (20.2) | 0.604 |
| D−/R+, n (%) | 31 (27.2) | 26 (23.9) | 0.646 |
| D+/R−, n (%) | 25 (21.9) | 23 (21.1) | 1.000 |
| D+/R+, n (%) | 37 (32.5) | 38 (34.9) | 0.777 |
| Cold ischemia time (hours) | 9.3±0.4 | 11.8±0.5 | * |
| Warm ischemia time (minutes) | 30.7±0.8 | 35.1±5.7 | 0.427 |
| Panel-reactive antibodies | |||
| Current (%) | 1.2±0.7 | 8.8±2.2 | * |
| Highest (%) | 5.7±1.5 | 15.3±2.7 | * |
| HLA mismatches (n) | 4.0±0.1 | 2.1±0.1 | * |
| Data are presented as mean±standard error of the mean (SEM) unless otherwise indicated. D – donor; ESKD – end-stage kidney disease; ESP – Eurotransplant Senior Program; ETKAS – Eurotransplant Kidney Allocation System; HLA – human leucocyte antigen; R – recipient. * | |||